|D012127||Respiratory Distress Syndrome, Newborn NIH||0.08|
|D055371||Acute Lung Injury NIH||0.08|
There is one clinical trial.
COVID-19 infection was shown to cause endothelial dysfunction . At the level of the endothelium the pathophysiological mechanisms have been hypothesized and were divided into pro-coagulant, pro-inflammatory, anti-fibrinolytics, impaired barrier function, vasoconstrictor and pro-oxidant. So far, the pro-coagulant and pro-inflammatory pathways have been studied and as a result dexamethasone and anticoagulation became part of the standard therapies for the disease. However, so far, no RCT has been evaluated on targeting the vasoconstrictive and antioxidant pathways with an aim of revealing clinical benefit. So, with this trial we intend to provide a regiment composed of several medications we hypothesize will act on several downstream pathways that would improve endothelial function primarily via the increase in NO production and release. At the time of this proposal there has been no randomized trials evaluating or testing the use of cardiovascular drugs targeting endothelial dysfunction in COVID-19 patients. As previously noted there has been a call to study these drugs and their effect after a strong research regarding their theorized effectiveness. For evidence, there was a recently published meta-analysis evaluating the role of statins in COVID-19 with preliminary findings suggested a reduction in fatal or severe disease by 30% and discredited the suggestion of harm, that emphasized on the need of well-designed randomized controlled trial to confirm the role of statins in COVID-19 patients. Our study would help determine the potential therapeutic effect of the endothelial protocol as adjunct to mainstream management. This study seeks to further our knowledge in treating COVID-19 to ultimately improve clinical outcomes and reduce complications.
Description: Clinical improvement was defined as improvement of at least two points from the baseline from date of intervention administration until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 1-month status on the six-category ordinal scale. This scale contains the subsequent categories: (1) death (2) hospital admission requiring invasive mechanical ventilation (3) hospital admission, requiring non-invasive positive pressure ventilation (4) hospital admission, requiring oxygen (5) hospital admission, not requiring oxygen (6) discharge.Measure: Clinical Improvement Time: From date of intervention administration until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 1 month
Description: Improvement in Laboratory Parameters: Troponin and D-dimerMeasure: Objective improvement Time: Troponin: Day 0, 2, 4, 8, 12, 14, 21, 28 D-dimer: within 48 hrs of admission, day 7, day 14, day 21, day 28.
Description: assess the patients in need of mechanical ventilationMeasure: Need for invasive mechanical ventilation Time: Assessment on daily basis for up to 1 month or until hospital discharge/death whichever came first
Description: Length of ICU stayMeasure: Length of ICU stay Time: Assessment on daily basis after the intervention is given for up to 1 month or until hospital discharge/death whichever came first
Description: Length of hospital StayMeasure: Length of hospital Stay Time: Assessment on daily basis after intervention given for up to 1 month or until hospital discharge/death whichever came first
Description: Length of need of mechanical ventilationMeasure: Length of need of mechanical ventilation Time: Assessment on daily basis after intervention given for up to 1 month or until hospital discharge/death whichever came first
Description: All cause mortalityMeasure: All cause mortality Time: assessed for up to 1 month
Description: Occurrence of side effectsMeasure: Occurrence of side effects Time: Assessment on daily basis after intervention given for up to 1 month or until hospital discharge/death whichever came first
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports